Conference Track

Resistance and Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2007 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

HIV Surveillance Study Reveals Drug Resistance in 10% of Newly Diagnosed Patients Across 11 US Regions
Very Low Rate of Resistance Associated With Lopinavir/Ritonavir Monotherapy by 48 Weeks Among Individuals in OK04 Trial
Emerging Lamivudine Resistance but Not Nevirapine Resistance Following PMTCT Treatment May Compromise Future HAART
Use of More Sensitive Assay Suggests Prevalence of Drug-Resistant HIV-1 Transmission May Be Underestimated
Darunavir Retains Activity Against Amprenavir-Resistant HIV-1 Despite Overlapping Resistance Profiles
Evolution of New Resistance Mutations May Be Detected in Seminal Fluid of HIV-Positive Men on Incompletely Suppressive Antiretroviral Therapy
Presence and Number of Genotypic Resistance Mutations Predicts Mortality Among Individuals With Triple-Class Antiretroviral Failure
Phenotypic Clinical Cutoffs for Susceptibility to Darunavir/Ritonavir Defined Using POWER Study Data
ACTG 5183: Addition of Cyclosporine A to Antiretroviral Therapy Not Associated With Prolonged Immunologic Benefit
Resistance in First Virologic Failure in HIV Subtype C Related to Adherence and Advanced Disease
High Frequency of Primary Lamivudine and Nelfinavir Resistance Mutations Among HIV-Infected Pregnant Women in United States
Infection With HIV-1 Non-B Subtypes Appears to Be Increasing Among HIV-Infected Blood Donors in the United States
ACTG 5214: Cytokine IL-7 Generally Well Tolerated With Beneficial Effect on T Cells
POWER Study Analysis: Prior Amprenavir Use/Resistance Has Limited Effect on 48-Week Response to Darunavir
Manon-02: HIV-Recombinant Canarypox Vaccine Associated With Increased HIV-1 Replication, Decreased Time of ART Interruption

Expert Analysis

Resistance and Management of Treatment-Experienced Patients

Faculty:
W. David Hardy, MD Kathleen E. Squires, MD Andrew R. Zolopa, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss the results of studies investigating the prevalence of transmitted antiretroviral resistance mutations
Recall data detailing the lack of clinically significant cross-resistance between amprenavir and darunavir
Describe the clinical significance of resistance mutations selected during antiretroviral therapy to prevent mother-to-child transmission of HIV
Specify data regarding the detection of low-level resistance mutations in minority viral populations
Summarize recent findings of the association between antiretroviral resistance and mortality

Topics covered include:

Postpartum Impact of Prevention of MTCT Strategies
Transmitted Resistance in Pregnant Women
Resistance in Non-B Subtypes
Ultrasensitive Genotypic Resistance Assays
Transmitted Antiretroviral Resistance
Independent Viral Evolution in Seminal Fluid
Resistance and Lopinavir/Ritonavir Monotherapy
Lack of Amprenavir-Darunavir Cross-Resistance
Correlation Between Resistance and Mortality
Therapeutic Strategies for Treatment-Experienced Patients

CME CREDIT INFORMATION

Release Date: 04/18/07

Expiration Date: 04/17/08

Physicians: maximum of 1.25 AMA PRA Category 1 Credit(s)™

Pharmacists: 1.3 contact hours (0.13 CEUs)

Registered Nurses: 1.3 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.